Abstract
Purpose:
To draw attention to a novel treatment agent for vision loss associated with peripheral exudative hemorrhagic chorioretinopathy.
Methods:
The case of an 83-year-old man suffering with loss of left visual acuity vision in the context of vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy is described.
Results:
Resolution of vitreous hemorrhage and subretinal hemorrhage was demonstrated after treatment with aflibercept.
Conclusion:
Peripheral exudative hemorrhagic chorioretinopathy is discussed in terms of its presentation, pathophysiology, and existing treatment methodologies.
MeSH terms
-
Aged, 80 and over
-
Angiogenesis Inhibitors / therapeutic use*
-
Central Serous Chorioretinopathy / diagnosis
-
Central Serous Chorioretinopathy / drug therapy*
-
Central Serous Chorioretinopathy / physiopathology
-
Exudates and Transudates
-
Humans
-
Intravitreal Injections
-
Male
-
Receptors, Vascular Endothelial Growth Factor / therapeutic use*
-
Recombinant Fusion Proteins / therapeutic use*
-
Retinal Hemorrhage / diagnosis
-
Retinal Hemorrhage / drug therapy*
-
Retinal Hemorrhage / physiopathology
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Visual Acuity / physiology
-
Vitreous Hemorrhage / diagnosis
-
Vitreous Hemorrhage / drug therapy*
-
Vitreous Hemorrhage / physiopathology
Substances
-
Angiogenesis Inhibitors
-
Recombinant Fusion Proteins
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
aflibercept
-
Receptors, Vascular Endothelial Growth Factor